Intelligence Feed event · Equity · 2026-10-13

    Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line Growth

    Question

    Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line Growth

    Direct answer

    Abbott Laboratories (ABT) closed up 2.23% at $101.82 on October 12, outperforming the benchmark S&P 500. The medical technology and healthcare company holds a Zacks Rank #2 (Buy) rating ahead of its third-quarter earnings release scheduled for October 21, 2026. Market consensus anticipates quarterly EPS of $1.42, a 9.23% increase year-over-year, alongside total quarterly revenue of $12.91 billion, reflecting a 13.52% increase from the prior-year quarter. Resilient procedure volumes across core cardiovascular and diabetes care segments support positive sentiment.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-13
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line Growth”, revision 1, evidence through 2026-10-13. https://marketontology.com/market-events/2026-10-13/abbott-laboratories-rises-2-2-ahead-of-q3-results-projecting-13-5-top-line-growt-f8418c

    EQUITY
    Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line Growth
    Abbott Laboratories (ABT) closed up 2.23% at $101.82 on October 12, outperforming the benchmark S&P 500. The medical technology and healthcare company holds a Zacks Rank #2 (Buy) rating ahead of its third-quarter earnings release scheduled for October 21, 2026. Market consensus anticipates quarterly EPS of $1.42, a 9.23% increase year-over-year, alongside total quarterly revenue of $12.91 billion, reflecting a 13.52% increase from the prior-year quarter. Resilient procedure volumes across core cardiovascular and diabetes care segments support positive sentiment.
    ABTXLVIHI
    Impact
    61
    OCT 13
    SIG
    85%
    ABTXLVIHI
    Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line Growth
    Abbott Laboratories (ABT) closed up 2.23% at $101.82 on October 12, outperforming the benchmark S&P 500. The medical technology and healthcare company holds a Zacks Rank #2 (Buy) rating ahead of its third-quarter earnings release scheduled for October 21, 2026. Market consensus anticipates quarterly EPS of $1.42, a 9.23% increase year-over-year, alongside total quarterly revenue of $12.91 billion, reflecting a 13.52% increase from the prior-year quarter. Resilient procedure volumes across core cardiovascular and diabetes care segments support positive sentiment.
    → Sustained medical device procedure volume growth and diagnostic demand drive Abbott Laboratories top-line expansion to $12.91 billion.
    Impact
    Abbott Laboratories (ABT) closed up 2.23% at $101.82 on October 12, outperforming the benchmark S&P 500. The medical technology and healthcare company holds a Zacks Rank #2 (Buy) rating ahead of its third-quarter earnings release scheduled for October 21, 2026. Market consensus anticipates quarterly EPS of $1.42, a 9.23% increase year-over-year, alongside total quarterly revenue of $12.91 billion, reflecting a 13.52% increase from the prior-year quarter. Resilient procedure volumes across core cardiovascular and diabetes care segments support positive sentiment.
    Affected
    ABTXLVIHI
    Transmission
    Sustained medical device procedure volume growth and diagnostic demand drive Abbott Laboratories top-line expansion to $12.91 billion.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ABTmedical device sales volume acceleration driving 13.52% revenue growthUp1-4wAbbott closed up 2.23% at $101.82 with Q3 revenue forecast of $12.91 billion.
    XLVdefensive large-cap healthcare multiple expansion from medtech earnings stabilityUp1-4wBroad healthcare sector constituents exhibited positive relative strength during session decline.
    IHIsurgical procedure recovery pass-through to medical device equipment indexUp1-4wAbbott is a core constituent in medical devices benchmark.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XLVUpagreed169.66 2026-10-13+2.53%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month